VEGFR-1 blockade with the monoclonal antibody D16F7 counteracts VEGF-A-induced tolerogenic and immune regulatory phenotypes without impairing T-cell activation
Despite the limitations of an in vitro PBMC-based system, selective VEGFR-1 blockade by D16F7 mAb alleviates VEGF-A-driven immune tolerance while preserving T-cell activation, supporting its translational potential as a complementary immunomodulatory approach.
Authors
- Pedro Miguel Lacal (ORCID: https://orcid.org/0000-0003-1166-4593)
- Ornella Franzese (ORCID: https://orcid.org/0000-0002-6396-4603)
- Graziani Grazia
- Belinda Palermo
Institutions
- University of Rome Tor Vergata (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- National Cancer Institute (MY)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1016/j.intimp.2026.116380
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00